CordenPharma Colorado Partners with BioMed Realty on Peptide Development Lab Expansion
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
BioMed Realty, the largest private owner and operator of real estate for the life science, technology, and innovation industries, announced that CordenPharma Colorado, a peptide drug substance contract development and manufacturing organization (CDMO), has leased 64,000 sqft at Flatiron Park near the existing CordenPharma Colorado facility.
Flatiron Park is BioMed Realty’s premier Boulder campus, supporting life science, quantum, and technology tenants. CordenPharma Colorado’s 15-year lease reinforces Flatiron Park’s position as a critical hub for innovation, and validates BioMed Realty’s substantial, long-term investment in the Boulder innovation ecosystem.
The new LEED Gold-certified facility features robust power capacity, adaptable lab grids, advanced mechanical and utility systems, and efficient waste disposal to support complex scientific operations. Strategically located adjacent to CordenPharma Colorado’s large-scale peptide manufacturing facility, the space will house process development and analytical services, enabling seamless integration of advanced peptide Active Pharmaceutical Ingredient (API) production from development through commercialization.
Beyond Colorado, the expanded peptide development capabilities created at this location will be integrated into CordenPharma’s growing global network across Europe and the US.
“We’re proud to deliver the first purpose-built lab building at Flatiron Park, designed to meet the flexibility and performance needs of sophisticated science users,” said Jon Bergschneider, President, West Coast Markets at BioMed Realty. “Combined with a connected campus experience, curated amenities, Discover Here programming, and a tenant-first operating model, Flatiron Park supports innovation today while enabling long-term growth.”
“We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region,” said Michael Landau, Managing Director of CordenPharma Colorado. “With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder. As a CDMO, our Development Laboratories are foundational in delivering effective support to customers and their patients.”
